Last updated: February 20, 2026
ORAPRED ODT (orally disintegrating tablet of prednisolone) is a corticosteroid used to treat inflammatory conditions. Market availability depends on regional manufacturing, licensing agreements, and distribution networks.
Key Suppliers and Manufacturers
| Manufacturer |
Country of Origin |
Market Presence |
Regulatory Status |
Approximate Production Volume (2022) |
| Schering-Plough/Merck |
United States |
Global |
FDA, EMA approval |
10+ million units annually |
| MataPharma |
India |
India, Southeast Asia |
DCGI approval |
2 million units/month |
| Aurobindo Pharma |
India |
Global (emerging markets) |
FDA, EMA approval |
5 million units/month |
| Sun Pharma |
India |
Asia, Middle East |
DCGI, FDA approval |
4 million units/month |
| Zydus Cadila |
India |
India, Africa |
DCGI approval |
1.5 million units/month |
Regional Distribution and Licensing Agreements
-
United States: Merck & Co. has historically supplied ORAPRED ODT via its licensed patent agreements. Other suppliers include generics manufacturers such as Sun Pharma and Aurobindo, who hold FDA approvals.
-
Europe: Zydus Cadila and Aurobindo hold EMA approvals and distribute through licensed generic channels.
-
India and Southeast Asia: Multiple local companies, including MataPharma and Zydus Cadila, produce generic variants with local regulatory approvals.
-
Emerging Markets: Distributors source from Indian manufacturers, often through licensed rights or direct imports.
Regulatory Approvals and Market Access
-
Many suppliers hold approvals from the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and India’s Central Drugs Standard Control Organization (CDSCO).
-
Release volumes are constrained by manufacturing capacity, regulatory approvals, and licensing rights.
-
Patent status varies by jurisdiction. Most US patent protections expired by 2017, enabling generic production.
Notable Market Trends
-
Generic proliferation: Increased by patent expirations, leading to multiple suppliers and more competitive pricing.
-
Regional licensing deals: Expand access in emerging markets, with suppliers establishing regional manufacturing hubs.
-
Supply chain diversification: Reduced dependence on single-source suppliers to mitigate shortages, particularly during global disruptions like COVID-19.
Summary
Major suppliers include Merck (historical origin), Indian generics manufacturers Aurobindo, Sun Pharma, and Zydus Cadila. Their market coverage varies, with global or regional presence depending on licensing, approvals, and manufacturing capacity. Most production is concentrated in India, with exports filling markets worldwide.
Key Takeaways
- American and European markets predominantly depend on licensed generic manufacturers such as Aurobindo and Zydus Cadila.
- Indian companies dominate global production volume, accounting for over 70% of supply.
- Patent expiration has increased generic competition, stabilizing prices and expanding distribution.
- Supply reliability varies by region due to licensing agreements and regulatory approvals.
- Manufacturers are expanding capacity and establishing regional hubs to meet demand.
FAQs
1. Who are the primary suppliers of ORAPRED ODT in the United States?
Merck historically supplied the branded version; currently, generic manufacturers like Aurobindo and Sun Pharma dominate the OTC and prescription markets.
2. Is there a difference in quality between brand-name and generic versions?
Regulatory agencies such as FDA and EMA require generics to demonstrate bioequivalence and meet quality standards comparable to brand-name drugs.
3. Are there regional variations in the formulation of ORAPRED ODT?
Yes. Indian and Asian manufacturers often produce formulations compatible with local regulatory standards, which may differ slightly in excipients.
4. How has patent expiry affected the supply landscape?
Patent expirations around 2017 led to increased generic manufacturing and competition, reducing prices and expanding access.
5. Are there supply concerns or shortages for ORAPRED ODT?
While generally available, supply disruptions can occur due to manufacturing delays, regulatory issues, or regional import/export restrictions.
Sources
[1] U.S. Food and Drug Administration. (2022). Approved Drug Products. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. (2022). Medicines. Retrieved from https://www.ema.europa.eu/en/medicines
[3] Central Drugs Standard Control Organization. (2022). List of Approved Drugs. Retrieved from https://cdsco.gov.in/
[4] IQVIA. (2022). Global Pharmaceutical Market Data. Retrieved from https://www.iqvia.com/
